{"protocolSection":{"identificationModule":{"nctId":"NCT03594747","orgStudyIdInfo":{"id":"BGB-A317-307"},"secondaryIdInfos":[{"id":"CTR20180292","type":"REGISTRY","domain":"ChinaDrugTrials"}],"organization":{"fullName":"BeiGene","class":"INDUSTRY"},"briefTitle":"A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer","officialTitle":"A Phase 3, Multicenter, Randomized Open-Label Study to Compare the Efficacy and Safety of Tislelizumab (BGB A317, Anti-PD1 Antibody) Combined With Paclitaxel Plus Carboplatin or Nab Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin Alone as First-Line Treatment for Untreated Advanced Squamous Non-small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2024-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2018-07-30","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2020-09-30","type":"ACTUAL"},"completionDateStruct":{"date":"2023-04-28","type":"ACTUAL"},"studyFirstSubmitDate":"2018-07-03","studyFirstSubmitQcDate":"2018-07-19","studyFirstPostDateStruct":{"date":"2018-07-20","type":"ACTUAL"},"resultsFirstSubmitDate":"2023-09-19","resultsFirstSubmitQcDate":"2023-10-13","resultsFirstPostDateStruct":{"date":"2023-10-17","type":"ACTUAL"},"dispFirstSubmitDate":"2021-09-24","dispFirstPostDateStruct":{"date":"2023-10-17","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-10-23","lastUpdatePostDateStruct":{"date":"2024-10-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"BeiGene","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"An open-label, randomized, multicenter Phase 3 study designed to compare the efficacy and safety of tislelizumab combined with chemotherapy versus chemotherapy only as first-line treatment in advanced squamous non-small cell lung cancer (NSCLC)."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":360,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Tislelizumab + Paclitaxel + Carboplatin","type":"EXPERIMENTAL","description":"Tislelizumab 200 milligrams (mg) plus paclitaxel 175 mg/m\\^2 and carboplatin area under the plasma or serum concentration-time curve (AUC) 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)","interventionNames":["Drug: Tislelizumab","Drug: Paclitaxel","Drug: Carboplatin"]},{"label":"Tislelizumab + Nab-paclitaxel + Carboplatin","type":"EXPERIMENTAL","description":"Tislelizumab 200 mg on Day 1 plus Nab-paclitaxel 100 mg/m\\^2 on Days 1, 8, and 15 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; Nab-paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)","interventionNames":["Drug: Tislelizumab","Drug: Nab-paclitaxel","Drug: Carboplatin"]},{"label":"Paclitaxel + Carboplatin","type":"ACTIVE_COMPARATOR","description":"Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks for 4 to 6 cycles (each cycle is 21 days)","interventionNames":["Drug: Paclitaxel","Drug: Carboplatin"]}],"interventions":[{"type":"DRUG","name":"Tislelizumab","description":"Administered intravenously as described","armGroupLabels":["Tislelizumab + Nab-paclitaxel + Carboplatin","Tislelizumab + Paclitaxel + Carboplatin"],"otherNames":["BGB-A317","Tevimbra"]},{"type":"DRUG","name":"Paclitaxel","description":"Administered intravenously as described","armGroupLabels":["Paclitaxel + Carboplatin","Tislelizumab + Paclitaxel + Carboplatin"]},{"type":"DRUG","name":"Nab-paclitaxel","description":"Administered intravenously as described","armGroupLabels":["Tislelizumab + Nab-paclitaxel + Carboplatin"]},{"type":"DRUG","name":"Carboplatin","description":"Administered intravenously as described","armGroupLabels":["Paclitaxel + Carboplatin","Tislelizumab + Nab-paclitaxel + Carboplatin","Tislelizumab + Paclitaxel + Carboplatin"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression Free Survival (PFS) by Independent Review Committee (IRC) Assessment as of Data Cut-off Date of 06DEC2019","description":"PFS is defined as the time from randomization until first documentation of disease progression as assessed by the IRC per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death from any cause, whichever occurs first","timeFrame":"Through primary analysis data cut-off date of 06DEC2019 (up to approximately 1 year and 4 months)"},{"measure":"PFS by IRC Assessment as of Data Cut-off Date of 30SEP2020","description":"PFS is defined as the time from randomization until first documentation of disease progression as assessed by the IRC per RECIST v1.1 or death from any cause, whichever occurs first","timeFrame":"Through primary analysis data cut-off date of 30SEP2020 (up to approximately 2 years and 2 months)"}],"secondaryOutcomes":[{"measure":"Overall Survival (OS)","description":"OS is defined as the time from randomization until the date of death due to any cause","timeFrame":"Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)"},{"measure":"Objective Response Rate (ORR) by IRC Assessment","description":"ORR is defined as the percentage of participants with complete response (CR) and partial response (PR), as assessed by the IRC using RECIST v1.1.","timeFrame":"Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)"},{"measure":"ORR by Investigator Assessment","description":"ORR is defined as the percentage of participants with complete response (CR) and partial response (PR), as assessed by the investigator using RECIST v1.1.","timeFrame":"Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)"},{"measure":"Duration of Response (DOR) by IRC Assessment","description":"DOR is defined as the time from the first occurrence of a documented objective response to the time of documented disease progression assessed by the IRC using RECIST v1.1, or death from any cause, whichever comes first, in all randomized participants with documented objective responses. Data are based on number of responders.","timeFrame":"Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)"},{"measure":"DOR by Investigator Assessment","description":"DOR is defined as the time from the first occurrence of a documented objective response to the time of documented disease progression assessed by the investigator using RECIST v1.1, or death from any cause, whichever comes first, in all randomized participants with documented objective responses. Data are based on number of responders.","timeFrame":"Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)"},{"measure":"PFS by Investigator Assessment","description":"PFS is defined as the time from randomization until first documentation of disease progression as assessed by the investigator per RECIST v1.1 or death from any cause, whichever occurs first","timeFrame":"Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)"},{"measure":"PFS by IRC Based on Programmed Death Ligand 1 (PD-L1) Expression","description":"PFS is defined as the time from randomization until first documentation of disease progression as assessed by the IRC per RECIST v1.1 or death from any cause, whichever occurs first, based on PD-L1 expression in tumor cells","timeFrame":"Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)"},{"measure":"European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer (EORTC QLQ-LC13)","description":"Least squares mean change from baseline in EORTC QLQ-CL13 scores for chest pain, coughing, and dyspnea between tislelizumab arms and paclitaxel + carboplatin arm. The EORTC QLQ-LC13 is a questionnaire that measures lung cancer-specific disease and treatment symptoms. It includes questions about specific symptoms in which participants respond based on a 4-point scale, where 1 is \"not at all\" and 4 is \"very much\". Raw scores are transformed into a 0 to 100 scale via linear transformation. A lower score indicates an improvement in symptoms.","timeFrame":"Baseline to Cycle 5; each cycle is 21 days"},{"measure":"European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status","description":"Least squares mean change from baseline in EORTC QLQ-C30 Global Health Status/Quality of Life score between tislelizumab arms and paclitaxel + carboplatin arm. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer patients. It includes global health status and quality of life questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.","timeFrame":"Baseline to Cycle 5; each cycle is 21 days"},{"measure":"Number of Participants With Adverse Events","description":"Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), which includes laboratory tests, physical exams, electrocardiogram results and vital signs, according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0","timeFrame":"From first dose to 30 days after the last dose (up to approximately 4 years and 9 months)"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n1. Age 18-75 years old, male or female, and signed informed consent form (ICF)\n2. Advanced NSCLC diagnosed by pathological or clinical physicians\n3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 1\n4. Participants must have ≥ 1 measurable lesion as defined per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\n5. Must be treatment-naive for locally advanced or metastatic squamous NSCLC\n6. Life expectancy ≥ 12 weeks\n7. Participants must have adequate organ function\n8. Male/Female is willing to use a highly effective method of birth control\n\nKey Exclusion Criteria:\n\n1. Diagnosed with NSCLC but with epidermal growth factor receptors (EGFR)-sensitizing mutation or anaplastic lymphoma kinase (ALK) gene translocation\n2. Received any approved systemic anticancer therapy\n3. Received prior treatment with EGFR inhibitors or ALK inhibitors\n4. Received prior therapies targeting programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1)\n5. With history of interstitial lung disease\n6. Clinically significant pericardial effusion\n7. Severe infections, active leptomeningeal disease or uncontrolled, untreated brain metastasis\n8. Any major surgical procedure before randomization\n9. Human immunodeficiency virus infection\n10. Untreated hepatitis B virus (HBV)/hepatitis C virus (HCV)\n11. Active autoimmune diseases or history of autoimmune diseases\n12. History of allergic reactions to chemotherapy\n\nNOTE: Other protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Study Director","affiliation":"BeiGene","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Anhui Provincial Hospital","city":"Hefei","state":"Anhui","zip":"230000","country":"China","geoPoint":{"lat":31.86389,"lon":117.28083}},{"facility":"The First Affiliated Hospital of Anhui Medical University","city":"Hefei","state":"Anhui","zip":"230000","country":"China","geoPoint":{"lat":31.86389,"lon":117.28083}},{"facility":"Cancer Hospital Chinese Academy of Medical Sciences","city":"Beijing","state":"Beijing Municipality","zip":"100021","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Beijing Cancer Hospital","city":"Beijing","state":"Beijing Municipality","zip":"100142","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Peking Union Medical College Hospital","city":"Beijing","state":"Beijing Municipality","zip":"100730","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Chinese Pla General Hospital","city":"Beijing","state":"Beijing Municipality","zip":"100853","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Beijing Chest Hospital, Capital Medical University","city":"Beijing","state":"Beijing Municipality","zip":"101149","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"The Second Affiliated Hospital of Chongqing Medical University","city":"Chongqing","state":"Chongqing Municipality","zip":"400010","country":"China","geoPoint":{"lat":29.56026,"lon":106.55771}},{"facility":"Southwest Hospital","city":"Chongqing","state":"Chongqing Municipality","zip":"400038","country":"China","geoPoint":{"lat":29.56026,"lon":106.55771}},{"facility":"Daping Hospital, Third Military Medical University","city":"Chongqing","state":"Chongqing Municipality","zip":"400042","country":"China","geoPoint":{"lat":29.56026,"lon":106.55771}},{"facility":"Chongqing Three Gorges Central Hospital","city":"Chongqing","state":"Chongqing Municipality","zip":"404000","country":"China","geoPoint":{"lat":29.56026,"lon":106.55771}},{"facility":"Fujian Cancer Hospital","city":"Fuzhou","state":"Fujian","zip":"350014","country":"China","geoPoint":{"lat":26.06139,"lon":119.30611}},{"facility":"The First Affiliated Hospital of Xiamen University","city":"Xiamen","state":"Fujian","zip":"361003","country":"China","geoPoint":{"lat":24.47979,"lon":118.08187}},{"facility":"Nanfang Hospital of Southern Medical University","city":"Guangzhou","state":"Guangdong","zip":"510515","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"Cancer Hospital of Shantou University Medical College","city":"Shantou","state":"Guangdong","zip":"515031","country":"China","geoPoint":{"lat":23.35489,"lon":116.67876}},{"facility":"The Peoples Hospital of Guangxi Zhuang Autonomous Region","city":"Nanning","state":"Guangxi","zip":"530021","country":"China","geoPoint":{"lat":22.81667,"lon":108.31667}},{"facility":"The Affiliated Hospital of Zunyi Medical College","city":"Zunyi","state":"Guizhou","zip":"563000","country":"China","geoPoint":{"lat":27.68667,"lon":106.90722}},{"facility":"Harbin Medical University Cancer Hospital","city":"Harbin","state":"Heilongjiang","zip":"150000","country":"China","geoPoint":{"lat":45.75,"lon":126.65}},{"facility":"Henan Cancer Hospital","city":"Zhengzhou","state":"Henan","zip":"450000","country":"China","geoPoint":{"lat":34.75778,"lon":113.64861}},{"facility":"The First Affiliated Hospital of Zhengzhou University","city":"Zhengzhou","state":"Henan","zip":"450052","country":"China","geoPoint":{"lat":34.75778,"lon":113.64861}},{"facility":"Union Hospital of Tongji Medical College, Huazhong University of Science and Technology","city":"Wuhan","state":"Hubei","zip":"430022","country":"China","geoPoint":{"lat":30.58333,"lon":114.26667}},{"facility":"Hubei Cancer Hospital","city":"Wuhan","state":"Hubei","zip":"430079","country":"China","geoPoint":{"lat":30.58333,"lon":114.26667}},{"facility":"The Second Xiangya Hospital of Central South University","city":"Changsha","state":"Hunan","zip":"410011","country":"China","geoPoint":{"lat":28.19874,"lon":112.97087}},{"facility":"Hunan Cancer Hospital","city":"Changsha","state":"Hunan","zip":"410013","country":"China","geoPoint":{"lat":28.19874,"lon":112.97087}},{"facility":"General Hospital of Eastern Theater Command","city":"Nanjing","state":"Jiangsu","zip":"210002","country":"China","geoPoint":{"lat":32.06167,"lon":118.77778}},{"facility":"The First Affiliated Hospital of Soochow University","city":"Suzhou","state":"Jiangsu","zip":"215006","country":"China","geoPoint":{"lat":31.30408,"lon":120.59538}},{"facility":"Xuzhou Central Hospital","city":"Xuzhou","state":"Jiangsu","zip":"221000","country":"China","geoPoint":{"lat":34.20442,"lon":117.28386}},{"facility":"The First Hospital of Jilin University","city":"Changchun","state":"Jilin","zip":"130021","country":"China","geoPoint":{"lat":43.88,"lon":125.32278}},{"facility":"Liaoning Cancer Hospital and Institute","city":"Shenyang","state":"Liaoning","zip":"110042","country":"China","geoPoint":{"lat":41.79222,"lon":123.43278}},{"facility":"The First Affiliated Hospital of Xian Jiaotong University","city":"Xi'an","state":"Shaanxi","zip":"710061","country":"China","geoPoint":{"lat":34.25833,"lon":108.92861}},{"facility":"Qilu Hospital of Shandong University","city":"Jinan","state":"Shandong","zip":"250000","country":"China","geoPoint":{"lat":36.66833,"lon":116.99722}},{"facility":"Jinan Central Hospital","city":"Jinan","state":"Shandong","zip":"250013","country":"China","geoPoint":{"lat":36.66833,"lon":116.99722}},{"facility":"Jinan Military General Hospital","city":"Jinan","state":"Shandong","zip":"250031","country":"China","geoPoint":{"lat":36.66833,"lon":116.99722}},{"facility":"Shandong Cancer Hospital","city":"Jinan","state":"Shandong","zip":"250117","country":"China","geoPoint":{"lat":36.66833,"lon":116.99722}},{"facility":"Weifang Peoples Hospital","city":"Weifang","state":"Shandong","zip":"261000","country":"China","geoPoint":{"lat":36.71,"lon":119.10194}},{"facility":"Shanghai Chest Hospital","city":"Shanghai","state":"Shanghai Municipality","zip":"200030","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"West China Hospital, Sichuan University","city":"Chengdu","state":"Sichuan","zip":"610041","country":"China","geoPoint":{"lat":30.66667,"lon":104.06667}},{"facility":"Tianjin Medical University General Hospital","city":"Tianjin","state":"Tianjin Municipality","zip":"300052","country":"China","geoPoint":{"lat":39.14222,"lon":117.17667}},{"facility":"Tianjin Medical University Cancer Institute and Hospital","city":"Tianjin","state":"Tianjin Municipality","zip":"300060","country":"China","geoPoint":{"lat":39.14222,"lon":117.17667}},{"facility":"The First Affiliated Hospital, Zhejiang University School of Medicine","city":"Hangzhou","state":"Zhejiang","zip":"310003","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"Hangzhou First Peoples Hospital","city":"Hangzhou","state":"Zhejiang","zip":"310006","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"Sir Run Run Shaw Hospital, Zhejiang University School of Medicine","city":"Hangzhou","state":"Zhejiang","zip":"310016","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"Zhejiang Cancer Hospital","city":"Hangzhou","state":"Zhejiang","zip":"310022","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}}]},"referencesModule":{"references":[{"pmid":"33792623","type":"BACKGROUND","citation":"Wang J, Lu S, Yu X, Hu Y, Sun Y, Wang Z, Zhao J, Yu Y, Hu C, Yang K, Feng G, Ying K, Zhuang W, Zhou J, Wu J, Leaw SJ, Zhang J, Lin X, Liang L, Yang N. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 May 1;7(5):709-717. doi: 10.1001/jamaoncol.2021.0366."},{"type":"BACKGROUND","citation":"Wang, J, S. Lu, et al. Randomized Phase III Study of Tislelizumab plus Chemotherapy versus Chemotherapy Alone as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer (Sq-NSCLC): RATIONALE-307 Updated Analysis. IOTECH Abstract, Vol. 16 Supplement 1, Dec. 2022. doi.org/10.1016/j.iotech.2022.100244."},{"pmid":"38052215","type":"DERIVED","citation":"Duan J, Zhang Y, Chen R, Liang L, Huo Y, Lu S, Zhao J, Hu C, Sun Y, Yang K, Chen M, Yu Y, Ying J, Huang R, Ma X, Leaw S, Bai F, Shen Z, Cai S, Gao D, Wang J, Wang Z. Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma. Cell Rep Med. 2023 Dec 19;4(12):101302. doi: 10.1016/j.xcrm.2023.101302. Epub 2023 Dec 4."}]},"ipdSharingStatementModule":{"ipdSharing":"YES"}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"This study was conducted at multiple study centers in China. Data are presented as of the study completion data cut-off date of 28APR2023.","groups":[{"id":"FG000","title":"Tislelizumab + Paclitaxel + Carboplatin","description":"Tislelizumab 200 milligrams (mg) plus paclitaxel 175 mg/m\\^2 and carboplatin area under the plasma or serum concentration-time curve (AUC) 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)"},{"id":"FG001","title":"Tislelizumab + Nab-paclitaxel + Carboplatin","description":"Tislelizumab 200 mg on Day 1 plus Nab-paclitaxel 100 mg/m\\^2 on Days 1, 8, and 15 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; Nab-paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)"},{"id":"FG002","title":"Paclitaxel + Carboplatin","description":"Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks for 4 to 6 cycles (each cycle is 21 days)"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"120"},{"groupId":"FG001","numSubjects":"119"},{"groupId":"FG002","numSubjects":"121"}]},{"type":"Randomized But Not Treated","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"4"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"120"},{"groupId":"FG001","numSubjects":"119"},{"groupId":"FG002","numSubjects":"121"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"78"},{"groupId":"FG001","numSubjects":"86"},{"groupId":"FG002","numSubjects":"87"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"11"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Sponsor decision","reasons":[{"groupId":"FG000","numSubjects":"23"},{"groupId":"FG001","numSubjects":"17"},{"groupId":"FG002","numSubjects":"16"}]},{"type":"Did not meet inclusion criteria","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Transfer to long term extension study","reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"5"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Intent-to-treat (ITT) analysis set included all participants who were randomized. Data are presented as of the study completion data cut-off date of 28APR2023.","groups":[{"id":"BG000","title":"Tislelizumab + Paclitaxel + Carboplatin","description":"Tislelizumab 200 milligrams (mg) plus paclitaxel 175 mg/m\\^2 and carboplatin area under the plasma or serum concentration-time curve (AUC) 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)"},{"id":"BG001","title":"Tislelizumab + Nab-paclitaxel + Carboplatin","description":"Tislelizumab 200 mg on Day 1 plus Nab-paclitaxel 100 mg/m\\^2 on Days 1, 8, and 15 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; Nab-paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)"},{"id":"BG002","title":"Paclitaxel + Carboplatin","description":"Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks for 4 to 6 cycles (each cycle is 21 days)"},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"120"},{"groupId":"BG001","value":"119"},{"groupId":"BG002","value":"121"},{"groupId":"BG003","value":"360"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"60.0","lowerLimit":"41","upperLimit":"75"},{"groupId":"BG001","value":"64.0","lowerLimit":"38","upperLimit":"74"},{"groupId":"BG002","value":"63.0","lowerLimit":"34","upperLimit":"75"},{"groupId":"BG003","value":"62.5","lowerLimit":"34","upperLimit":"75"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"30"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"107"},{"groupId":"BG001","value":"112"},{"groupId":"BG002","value":"111"},{"groupId":"BG003","value":"330"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"120"},{"groupId":"BG001","value":"119"},{"groupId":"BG002","value":"121"},{"groupId":"BG003","value":"360"}]}]},{"title":"Not Hispanic or Latino","categories":[{"measurements":[{"groupId":"BG000","value":"120"},{"groupId":"BG001","value":"119"},{"groupId":"BG002","value":"121"},{"groupId":"BG003","value":"360"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival (PFS) by Independent Review Committee (IRC) Assessment as of Data Cut-off Date of 06DEC2019","description":"PFS is defined as the time from randomization until first documentation of disease progression as assessed by the IRC per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death from any cause, whichever occurs first","populationDescription":"ITT analysis set included all participants who were randomized","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Through primary analysis data cut-off date of 06DEC2019 (up to approximately 1 year and 4 months)","groups":[{"id":"OG000","title":"Tislelizumab + Paclitaxel + Carboplatin","description":"Tislelizumab 200 milligrams (mg) plus paclitaxel 175 mg/m\\^2 and carboplatin area under the plasma or serum concentration-time curve (AUC) 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)"},{"id":"OG001","title":"Tislelizumab + Nab-paclitaxel + Carboplatin","description":"Tislelizumab 200 mg on Day 1 plus Nab-paclitaxel 100 mg/m\\^2 on Days 1, 8, and 15 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; Nab-paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)"},{"id":"OG002","title":"Paclitaxel + Carboplatin","description":"Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks for 4 to 6 cycles (each cycle is 21 days)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"120"},{"groupId":"OG001","value":"119"},{"groupId":"OG002","value":"121"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","lowerLimit":"5.95","upperLimit":"9.79"},{"groupId":"OG001","value":"7.6","lowerLimit":"5.75","upperLimit":"11.01"},{"groupId":"OG002","value":"5.5","lowerLimit":"4.21","upperLimit":"5.65"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0001","statisticalMethod":"One-sided stratified log-rank test","paramType":"Hazard Ratio (HR)","paramValue":"0.52","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.37","ciUpperLimit":"0.74"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"One-sided stratified log-rank test","paramType":"Hazard Ratio (HR)","paramValue":"0.47","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.33","ciUpperLimit":"0.67"}]},{"type":"PRIMARY","title":"PFS by IRC Assessment as of Data Cut-off Date of 30SEP2020","description":"PFS is defined as the time from randomization until first documentation of disease progression as assessed by the IRC per RECIST v1.1 or death from any cause, whichever occurs first","populationDescription":"ITT analysis set included all participants who were randomized","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Through primary analysis data cut-off date of 30SEP2020 (up to approximately 2 years and 2 months)","groups":[{"id":"OG000","title":"Tislelizumab + Paclitaxel + Carboplatin","description":"Tislelizumab 200 milligrams (mg) plus paclitaxel 175 mg/m\\^2 and carboplatin area under the plasma or serum concentration-time curve (AUC) 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)"},{"id":"OG001","title":"Tislelizumab + Nab-paclitaxel + Carboplatin","description":"Tislelizumab 200 mg on Day 1 plus Nab-paclitaxel 100 mg/m\\^2 on Days 1, 8, and 15 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; Nab-paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)"},{"id":"OG002","title":"Paclitaxel + Carboplatin","description":"Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks for 4 to 6 cycles (each cycle is 21 days)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"120"},{"groupId":"OG001","value":"119"},{"groupId":"OG002","value":"121"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","lowerLimit":"6.74","upperLimit":"10.41"},{"groupId":"OG001","value":"9.6","lowerLimit":"7.39","upperLimit":"10.78"},{"groupId":"OG002","value":"5.5","lowerLimit":"4.21","upperLimit":"5.59"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.45","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.32","ciUpperLimit":"0.61"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.42","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.30","ciUpperLimit":"0.59"}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS is defined as the time from randomization until the date of death due to any cause","populationDescription":"ITT analysis set included all participants who were randomized","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)","groups":[{"id":"OG000","title":"Tislelizumab + Paclitaxel + Carboplatin","description":"Tislelizumab 200 milligrams (mg) plus paclitaxel 175 mg/m\\^2 and carboplatin area under the plasma or serum concentration-time curve (AUC) 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)"},{"id":"OG001","title":"Tislelizumab + Nab-paclitaxel + Carboplatin","description":"Tislelizumab 200 mg on Day 1 plus Nab-paclitaxel 100 mg/m\\^2 on Days 1, 8, and 15 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; Nab-paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)"},{"id":"OG002","title":"Paclitaxel + Carboplatin","description":"Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks for 4 to 6 cycles (each cycle is 21 days)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"120"},{"groupId":"OG001","value":"119"},{"groupId":"OG002","value":"121"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.1","lowerLimit":"18.99","upperLimit":"33.81"},{"groupId":"OG001","value":"23.3","lowerLimit":"18.76","upperLimit":"26.38"},{"groupId":"OG002","value":"19.4","lowerLimit":"15.97","upperLimit":"23.43"}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR) by IRC Assessment","description":"ORR is defined as the percentage of participants with complete response (CR) and partial response (PR), as assessed by the IRC using RECIST v1.1.","populationDescription":"ITT analysis set included all participants who were randomized","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)","groups":[{"id":"OG000","title":"Tislelizumab + Paclitaxel + Carboplatin","description":"Tislelizumab 200 milligrams (mg) plus paclitaxel 175 mg/m\\^2 and carboplatin area under the plasma or serum concentration-time curve (AUC) 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)"},{"id":"OG001","title":"Tislelizumab + Nab-paclitaxel + Carboplatin","description":"Tislelizumab 200 mg on Day 1 plus Nab-paclitaxel 100 mg/m\\^2 on Days 1, 8, and 15 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; Nab-paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)"},{"id":"OG002","title":"Paclitaxel + Carboplatin","description":"Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks for 4 to 6 cycles (each cycle is 21 days)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"120"},{"groupId":"OG001","value":"119"},{"groupId":"OG002","value":"121"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.2","lowerLimit":"65.4","upperLimit":"81.7"},{"groupId":"OG001","value":"73.9","lowerLimit":"65.1","upperLimit":"81.6"},{"groupId":"OG002","value":"47.9","lowerLimit":"38.8","upperLimit":"57.2"}]}]}]},{"type":"SECONDARY","title":"ORR by Investigator Assessment","description":"ORR is defined as the percentage of participants with complete response (CR) and partial response (PR), as assessed by the investigator using RECIST v1.1.","populationDescription":"ITT analysis set included all participants who were randomized","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)","groups":[{"id":"OG000","title":"Tislelizumab + Paclitaxel + Carboplatin","description":"Tislelizumab 200 milligrams (mg) plus paclitaxel 175 mg/m\\^2 and carboplatin area under the plasma or serum concentration-time curve (AUC) 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)"},{"id":"OG001","title":"Tislelizumab + Nab-paclitaxel + Carboplatin","description":"Tislelizumab 200 mg on Day 1 plus Nab-paclitaxel 100 mg/m\\^2 on Days 1, 8, and 15 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; Nab-paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)"},{"id":"OG002","title":"Paclitaxel + Carboplatin","description":"Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks for 4 to 6 cycles (each cycle is 21 days)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"120"},{"groupId":"OG001","value":"119"},{"groupId":"OG002","value":"121"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.0","lowerLimit":"61.0","upperLimit":"78.0"},{"groupId":"OG001","value":"78.2","lowerLimit":"69.6","upperLimit":"85.2"},{"groupId":"OG002","value":"49.6","lowerLimit":"40.4","upperLimit":"58.8"}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DOR) by IRC Assessment","description":"DOR is defined as the time from the first occurrence of a documented objective response to the time of documented disease progression assessed by the IRC using RECIST v1.1, or death from any cause, whichever comes first, in all randomized participants with documented objective responses. Data are based on number of responders.","populationDescription":"ITT analysis set included all participants who were randomized","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)","groups":[{"id":"OG000","title":"Tislelizumab + Paclitaxel + Carboplatin","description":"Tislelizumab 200 milligrams (mg) plus paclitaxel 175 mg/m\\^2 and carboplatin area under the plasma or serum concentration-time curve (AUC) 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)"},{"id":"OG001","title":"Tislelizumab + Nab-paclitaxel + Carboplatin","description":"Tislelizumab 200 mg on Day 1 plus Nab-paclitaxel 100 mg/m\\^2 on Days 1, 8, and 15 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; Nab-paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)"},{"id":"OG002","title":"Paclitaxel + Carboplatin","description":"Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks for 4 to 6 cycles (each cycle is 21 days)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"88"},{"groupId":"OG002","value":"58"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.4","lowerLimit":"5.03","upperLimit":"18.69"},{"groupId":"OG001","value":"8.6","lowerLimit":"7.13","upperLimit":"12.48"},{"groupId":"OG002","value":"4.3","lowerLimit":"2.86","upperLimit":"5.42"}]}]}]},{"type":"SECONDARY","title":"DOR by Investigator Assessment","description":"DOR is defined as the time from the first occurrence of a documented objective response to the time of documented disease progression assessed by the investigator using RECIST v1.1, or death from any cause, whichever comes first, in all randomized participants with documented objective responses. Data are based on number of responders.","populationDescription":"ITT analysis set included all participants who were randomized","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)","groups":[{"id":"OG000","title":"Tislelizumab + Paclitaxel + Carboplatin","description":"Tislelizumab 200 milligrams (mg) plus paclitaxel 175 mg/m\\^2 and carboplatin area under the plasma or serum concentration-time curve (AUC) 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)"},{"id":"OG001","title":"Tislelizumab + Nab-paclitaxel + Carboplatin","description":"Tislelizumab 200 mg on Day 1 plus Nab-paclitaxel 100 mg/m\\^2 on Days 1, 8, and 15 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; Nab-paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)"},{"id":"OG002","title":"Paclitaxel + Carboplatin","description":"Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks for 4 to 6 cycles (each cycle is 21 days)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"93"},{"groupId":"OG002","value":"60"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6","lowerLimit":"7.03","upperLimit":"16.23"},{"groupId":"OG001","value":"8.8","lowerLimit":"8.05","upperLimit":"11.93"},{"groupId":"OG002","value":"4.8","lowerLimit":"2.86","upperLimit":"6.11"}]}]}]},{"type":"SECONDARY","title":"PFS by Investigator Assessment","description":"PFS is defined as the time from randomization until first documentation of disease progression as assessed by the investigator per RECIST v1.1 or death from any cause, whichever occurs first","populationDescription":"ITT analysis set included all participants who were randomized","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)","groups":[{"id":"OG000","title":"Tislelizumab + Paclitaxel + Carboplatin","description":"Tislelizumab 200 milligrams (mg) plus paclitaxel 175 mg/m\\^2 and carboplatin area under the plasma or serum concentration-time curve (AUC) 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)"},{"id":"OG001","title":"Tislelizumab + Nab-paclitaxel + Carboplatin","description":"Tislelizumab 200 mg on Day 1 plus Nab-paclitaxel 100 mg/m\\^2 on Days 1, 8, and 15 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; Nab-paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)"},{"id":"OG002","title":"Paclitaxel + Carboplatin","description":"Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks for 4 to 6 cycles (each cycle is 21 days)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"120"},{"groupId":"OG001","value":"119"},{"groupId":"OG002","value":"121"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","lowerLimit":"7.62","upperLimit":"11.76"},{"groupId":"OG001","value":"9.8","lowerLimit":"8.57","upperLimit":"11.86"},{"groupId":"OG002","value":"5.5","lowerLimit":"4.17","upperLimit":"5.65"}]}]}]},{"type":"SECONDARY","title":"PFS by IRC Based on Programmed Death Ligand 1 (PD-L1) Expression","description":"PFS is defined as the time from randomization until first documentation of disease progression as assessed by the IRC per RECIST v1.1 or death from any cause, whichever occurs first, based on PD-L1 expression in tumor cells","populationDescription":"ITT analysis set included all participants who were randomized; participants evaluable for PD-L1 expression were included","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)","groups":[{"id":"OG000","title":"Tislelizumab + Paclitaxel + Carboplatin","description":"Tislelizumab 200 milligrams (mg) plus paclitaxel 175 mg/m\\^2 and carboplatin area under the plasma or serum concentration-time curve (AUC) 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)"},{"id":"OG001","title":"Tislelizumab + Nab-paclitaxel + Carboplatin","description":"Tislelizumab 200 mg on Day 1 plus Nab-paclitaxel 100 mg/m\\^2 on Days 1, 8, and 15 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; Nab-paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)"},{"id":"OG002","title":"Paclitaxel + Carboplatin","description":"Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks for 4 to 6 cycles (each cycle is 21 days)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"118"},{"groupId":"OG002","value":"117"}]}],"classes":[{"title":"PD-L Expression (<1%)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"46"},{"groupId":"OG002","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","lowerLimit":"5.5","upperLimit":"14.5"},{"groupId":"OG001","value":"7.6","lowerLimit":"5.4","upperLimit":"9.9"},{"groupId":"OG002","value":"5.5","lowerLimit":"4.2","upperLimit":"7.0"}]}]},{"title":"PD-L Expression (1% to 49%)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.9","lowerLimit":"5.5","upperLimit":"22.7"},{"groupId":"OG001","value":"9.8","lowerLimit":"7.6","upperLimit":"12.0"},{"groupId":"OG002","value":"5.0","lowerLimit":"2.8","upperLimit":"6.5"}]}]},{"title":"PD-L Expression (≥ 50%)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"41"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","lowerLimit":"5.9","upperLimit":"9.8"},{"groupId":"OG001","value":"9.7","lowerLimit":"5.6","upperLimit":"30.9"},{"groupId":"OG002","value":"5.5","lowerLimit":"4.1","upperLimit":"5.6"}]}]}]},{"type":"SECONDARY","title":"European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer (EORTC QLQ-LC13)","description":"Least squares mean change from baseline in EORTC QLQ-CL13 scores for chest pain, coughing, and dyspnea between tislelizumab arms and paclitaxel + carboplatin arm. The EORTC QLQ-LC13 is a questionnaire that measures lung cancer-specific disease and treatment symptoms. It includes questions about specific symptoms in which participants respond based on a 4-point scale, where 1 is \"not at all\" and 4 is \"very much\". Raw scores are transformed into a 0 to 100 scale via linear transformation. A lower score indicates an improvement in symptoms.","populationDescription":"Health-Related Quality of Life (HRQoL) analysis set included all randomized participants who received ≥ 1 dose of study drug and completed ≥ HRQoL assessment post baseline","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Score on a scale","timeFrame":"Baseline to Cycle 5; each cycle is 21 days","groups":[{"id":"OG000","title":"Tislelizumab + Paclitaxel + Carboplatin","description":"Tislelizumab 200 milligrams (mg) plus paclitaxel 175 mg/m\\^2 and carboplatin area under the plasma or serum concentration-time curve (AUC) 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)"},{"id":"OG001","title":"Tislelizumab + Nab-paclitaxel + Carboplatin","description":"Tislelizumab 200 mg on Day 1 plus Nab-paclitaxel 100 mg/m\\^2 on Days 1, 8, and 15 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; Nab-paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"120"},{"groupId":"OG001","value":"118"}]}],"classes":[{"title":"Chest pain","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"-5.0","upperLimit":"5.9"},{"groupId":"OG001","value":"-0.4","lowerLimit":"-5.9","upperLimit":"5.1"}]}]},{"title":"Coughing","categories":[{"measurements":[{"groupId":"OG000","value":"-7.0","lowerLimit":"-14.3","upperLimit":"0.2"},{"groupId":"OG001","value":"-0.4","lowerLimit":"-7.7","upperLimit":"6.8"}]}]},{"title":"Dyspnea","categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","lowerLimit":"-6.9","upperLimit":"1.6"},{"groupId":"OG001","value":"-1.0","lowerLimit":"-5.3","upperLimit":"3.3"}]}]}]},{"type":"SECONDARY","title":"European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status","description":"Least squares mean change from baseline in EORTC QLQ-C30 Global Health Status/Quality of Life score between tislelizumab arms and paclitaxel + carboplatin arm. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer patients. It includes global health status and quality of life questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.","populationDescription":"HRQoL analysis set included all randomized participants who received ≥ 1 dose of study drug and completed ≥ HRQoL assessment post baseline","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Score on a scale","timeFrame":"Baseline to Cycle 5; each cycle is 21 days","groups":[{"id":"OG000","title":"Tislelizumab + Paclitaxel + Carboplatin","description":"Tislelizumab 200 milligrams (mg) plus paclitaxel 175 mg/m\\^2 and carboplatin area under the plasma or serum concentration-time curve (AUC) 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)"},{"id":"OG001","title":"Tislelizumab + Nab-paclitaxel + Carboplatin","description":"Tislelizumab 200 mg on Day 1 plus Nab-paclitaxel 100 mg/m\\^2 on Days 1, 8, and 15 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; Nab-paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"120"},{"groupId":"OG001","value":"118"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","lowerLimit":"-3.4","upperLimit":"8.2"},{"groupId":"OG001","value":"3.3","lowerLimit":"-2.5","upperLimit":"9.2"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events","description":"Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), which includes laboratory tests, physical exams, electrocardiogram results and vital signs, according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0","populationDescription":"Safety analysis set included all randomized participants who received ≥ 1 dose of any study treatment","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose to 30 days after the last dose (up to approximately 4 years and 9 months)","groups":[{"id":"OG000","title":"Tislelizumab + Paclitaxel + Carboplatin","description":"Tislelizumab 200 milligrams (mg) plus paclitaxel 175 mg/m\\^2 and carboplatin area under the plasma or serum concentration-time curve (AUC) 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)"},{"id":"OG001","title":"Tislelizumab + Nab-paclitaxel + Carboplatin","description":"Tislelizumab 200 mg on Day 1 plus Nab-paclitaxel 100 mg/m\\^2 on Days 1, 8, and 15 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; Nab-paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)"},{"id":"OG002","title":"Paclitaxel + Carboplatin","description":"Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks for 4 to 6 cycles (each cycle is 21 days)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"120"},{"groupId":"OG001","value":"118"},{"groupId":"OG002","value":"117"}]}],"classes":[{"title":"At least 1 TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"120"},{"groupId":"OG001","value":"117"},{"groupId":"OG002","value":"117"}]}]},{"title":"At least 1 SAE","categories":[{"measurements":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"29"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"3","timeFrame":"From the first dose up to 30 days after the last dose of study drug, up to approximately 4 years and 9 months","description":"All-cause mortality is reported for all randomized participants. Serious and other adverse events includes all randomized participants who received ≥ 1 dose of any study treatment","eventGroups":[{"id":"EG000","title":"Tislelizumab + Paclitaxel + Carboplatin","description":"Tislelizumab 200 milligrams (mg) plus paclitaxel 175 mg/m\\^2 and carboplatin area under the plasma or serum concentration-time curve (AUC) 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)","deathsNumAffected":78,"deathsNumAtRisk":120,"seriousNumAffected":56,"seriousNumAtRisk":120,"otherNumAffected":119,"otherNumAtRisk":120},{"id":"EG001","title":"Tislelizumab + Nab-Paclitaxel + Carboplatin","description":"Tislelizumab 200 mg on Day 1 plus Nab-paclitaxel 100 mg/m\\^2 on Days 1, 8, and 15 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; Nab-paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)","deathsNumAffected":86,"deathsNumAtRisk":119,"seriousNumAffected":55,"seriousNumAtRisk":118,"otherNumAffected":117,"otherNumAtRisk":118},{"id":"EG002","title":"Paclitaxel + Carboplatin","description":"Paclitaxel 175 mg/m\\^2 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks for 4 to 6 cycles (each cycle is 21 days)","deathsNumAffected":87,"deathsNumAtRisk":121,"seriousNumAffected":29,"seriousNumAtRisk":117,"otherNumAffected":116,"otherNumAtRisk":117}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":117}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":120},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":118},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Hypofibrinogenaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Myelosuppression","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Splenic haemorrhage","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":117}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Immune-mediated myocarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Myocarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Sinus tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Autoimmune thyroiditis","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Ascites","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Oesophageal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":117}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Cyst","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":118},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":117}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Multiple organ dysfunction syndrome","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Puncture site haemorrhage","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":117}]},{"term":"Hepatic failure","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Hepatic function abnormal","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Immune-mediated hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"COVID-19 pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Pneumocystis jirovecii pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":12,"numAtRisk":120},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":118},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":117}]},{"term":"Pulmonary tuberculosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Pyelonephritis acute","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Rash pustular","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":117}]},{"term":"Tuberculous pleurisy","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Ankle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Cerebral radiation injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Post procedural haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Spinal compression fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Tibia fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Electrocardiogram ST-T segment abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":120},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":118},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":117}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":117}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Hypoproteinaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Type 1 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Immune-mediated arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Pathological fracture","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Gastrointestinal stromal tumour","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Pituitary tumour benign","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Facial paralysis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Hydrocephalus","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Immune-mediated encephalitis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Thinking abnormal","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Ureterolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Atelectasis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Bronchostenosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":120},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":118},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Immune-mediated lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":120},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":118},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Laryngeal obstruction","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":120},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":3,"numAffected":1,"numAtRisk":117}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Drug eruption","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Psoriasis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Rash erythematous","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":118},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":277,"numAffected":107,"numAtRisk":120},{"groupId":"EG001","numEvents":297,"numAffected":111,"numAtRisk":118},{"groupId":"EG002","numEvents":198,"numAffected":94,"numAtRisk":117}]},{"term":"Leukocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":120},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":118},{"groupId":"EG002","numEvents":11,"numAffected":7,"numAtRisk":117}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":234,"numAffected":58,"numAtRisk":120},{"groupId":"EG001","numEvents":291,"numAffected":66,"numAtRisk":118},{"groupId":"EG002","numEvents":187,"numAffected":57,"numAtRisk":117}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":191,"numAffected":53,"numAtRisk":120},{"groupId":"EG001","numEvents":196,"numAffected":50,"numAtRisk":118},{"groupId":"EG002","numEvents":160,"numAffected":56,"numAtRisk":117}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":89,"numAffected":36,"numAtRisk":120},{"groupId":"EG001","numEvents":131,"numAffected":48,"numAtRisk":118},{"groupId":"EG002","numEvents":54,"numAffected":33,"numAtRisk":117}]},{"term":"Sinus bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":2,"numAtRisk":120},{"groupId":"EG001","numEvents":12,"numAffected":5,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Supraventricular extrasystoles","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":120},{"groupId":"EG001","numEvents":14,"numAffected":5,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Ventricular extrasystoles","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":120},{"groupId":"EG001","numEvents":7,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":120},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":42,"numAffected":19,"numAtRisk":120},{"groupId":"EG001","numEvents":26,"numAffected":16,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":120},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":118},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":117}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":120},{"groupId":"EG001","numEvents":12,"numAffected":10,"numAtRisk":118},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":117}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":120},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":118},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":117}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":7,"numAtRisk":120},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":118},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":117}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":48,"numAffected":40,"numAtRisk":120},{"groupId":"EG001","numEvents":50,"numAffected":36,"numAtRisk":118},{"groupId":"EG002","numEvents":30,"numAffected":27,"numAtRisk":117}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":32,"numAffected":21,"numAtRisk":120},{"groupId":"EG001","numEvents":41,"numAffected":24,"numAtRisk":118},{"groupId":"EG002","numEvents":9,"numAffected":8,"numAtRisk":117}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":120},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":118},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":120},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":118},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":68,"numAffected":37,"numAtRisk":120},{"groupId":"EG001","numEvents":87,"numAffected":54,"numAtRisk":118},{"groupId":"EG002","numEvents":51,"numAffected":35,"numAtRisk":117}]},{"term":"Oral pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":120},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":118},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":117}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":120},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":120},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":118},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":117}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":41,"numAffected":28,"numAtRisk":120},{"groupId":"EG001","numEvents":41,"numAffected":26,"numAtRisk":118},{"groupId":"EG002","numEvents":25,"numAffected":19,"numAtRisk":117}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":38,"numAffected":30,"numAtRisk":120},{"groupId":"EG001","numEvents":32,"numAffected":24,"numAtRisk":118},{"groupId":"EG002","numEvents":33,"numAffected":23,"numAtRisk":117}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":120},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":118},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":120},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":118},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":117}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":5,"numAtRisk":120},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":118},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":117}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":35,"numAffected":22,"numAtRisk":120},{"groupId":"EG001","numEvents":32,"numAffected":19,"numAtRisk":118},{"groupId":"EG002","numEvents":31,"numAffected":19,"numAtRisk":117}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":120},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":118},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":117}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":120},{"groupId":"EG001","numEvents":12,"numAffected":7,"numAtRisk":118},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":117}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":8,"numAtRisk":120},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":118},{"groupId":"EG002","numEvents":10,"numAffected":6,"numAtRisk":117}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":32,"numAffected":25,"numAtRisk":120},{"groupId":"EG001","numEvents":40,"numAffected":24,"numAtRisk":118},{"groupId":"EG002","numEvents":23,"numAffected":17,"numAtRisk":117}]},{"term":"Hepatic function abnormal","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":7,"numAtRisk":120},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":118},{"groupId":"EG002","numEvents":11,"numAffected":10,"numAtRisk":117}]},{"term":"Drug hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":118},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":117}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":120},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":118},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":15,"numAtRisk":120},{"groupId":"EG001","numEvents":17,"numAffected":13,"numAtRisk":118},{"groupId":"EG002","numEvents":10,"numAffected":8,"numAtRisk":117}]},{"term":"Rash pustular","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":20,"numAtRisk":120},{"groupId":"EG001","numEvents":23,"numAffected":15,"numAtRisk":118},{"groupId":"EG002","numEvents":13,"numAffected":11,"numAtRisk":117}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":120},{"groupId":"EG001","numEvents":8,"numAffected":5,"numAtRisk":118},{"groupId":"EG002","numEvents":7,"numAffected":4,"numAtRisk":117}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":131,"numAffected":57,"numAtRisk":120},{"groupId":"EG001","numEvents":82,"numAffected":46,"numAtRisk":118},{"groupId":"EG002","numEvents":42,"numAffected":27,"numAtRisk":117}]},{"term":"Alpha hydroxybutyrate dehydrogenase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":6,"numAtRisk":120},{"groupId":"EG001","numEvents":5,"numAffected":2,"numAtRisk":118},{"groupId":"EG002","numEvents":8,"numAffected":4,"numAtRisk":117}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":120,"numAffected":52,"numAtRisk":120},{"groupId":"EG001","numEvents":82,"numAffected":44,"numAtRisk":118},{"groupId":"EG002","numEvents":19,"numAffected":14,"numAtRisk":117}]},{"term":"Bilirubin conjugated increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":6,"numAtRisk":120},{"groupId":"EG001","numEvents":9,"numAffected":4,"numAtRisk":118},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":117}]},{"term":"Blood albumin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":120},{"groupId":"EG001","numEvents":9,"numAffected":5,"numAtRisk":118},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":117}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":20,"numAtRisk":120},{"groupId":"EG001","numEvents":21,"numAffected":12,"numAtRisk":118},{"groupId":"EG002","numEvents":18,"numAffected":11,"numAtRisk":117}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":94,"numAffected":31,"numAtRisk":120},{"groupId":"EG001","numEvents":46,"numAffected":21,"numAtRisk":118},{"groupId":"EG002","numEvents":22,"numAffected":15,"numAtRisk":117}]},{"term":"Blood bilirubin unconjugated increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":5,"numAtRisk":120},{"groupId":"EG001","numEvents":10,"numAffected":5,"numAtRisk":118},{"groupId":"EG002","numEvents":6,"numAffected":4,"numAtRisk":117}]},{"term":"Blood chloride decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":120},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":118},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":117}]},{"term":"Blood cholesterol increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":3,"numAtRisk":120},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":118},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":117}]},{"term":"Blood creatine phosphokinase MB increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":5,"numAtRisk":120},{"groupId":"EG001","numEvents":12,"numAffected":6,"numAtRisk":118},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":117}]},{"term":"Blood creatine phosphokinase decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":120},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":118},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":117}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":47,"numAffected":22,"numAtRisk":120},{"groupId":"EG001","numEvents":56,"numAffected":16,"numAtRisk":118},{"groupId":"EG002","numEvents":14,"numAffected":10,"numAtRisk":117}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":7,"numAtRisk":120},{"groupId":"EG001","numEvents":36,"numAffected":11,"numAtRisk":118},{"groupId":"EG002","numEvents":10,"numAffected":7,"numAtRisk":117}]},{"term":"Blood fibrinogen increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":120},{"groupId":"EG001","numEvents":14,"numAffected":4,"numAtRisk":118},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":117}]},{"term":"Blood glucose increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":120},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":118},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Blood lactate dehydrogenase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":45,"numAffected":23,"numAtRisk":120},{"groupId":"EG001","numEvents":33,"numAffected":20,"numAtRisk":118},{"groupId":"EG002","numEvents":20,"numAffected":13,"numAtRisk":117}]},{"term":"Blood magnesium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":120},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":118},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":117}]},{"term":"Blood potassium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Blood thyroid stimulating hormone decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":120},{"groupId":"EG001","numEvents":17,"numAffected":9,"numAtRisk":118},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Blood thyroid stimulating hormone increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":10,"numAtRisk":120},{"groupId":"EG001","numEvents":24,"numAffected":9,"numAtRisk":118},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Blood urea increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":120},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":118},{"groupId":"EG002","numEvents":7,"numAffected":4,"numAtRisk":117}]},{"term":"Electrocardiogram QT prolonged","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Electrocardiogram T wave abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":120},{"groupId":"EG001","numEvents":20,"numAffected":4,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Fibrin D dimer increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":120},{"groupId":"EG001","numEvents":10,"numAffected":4,"numAtRisk":118},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":117}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":47,"numAffected":21,"numAtRisk":120},{"groupId":"EG001","numEvents":30,"numAffected":18,"numAtRisk":118},{"groupId":"EG002","numEvents":20,"numAffected":15,"numAtRisk":117}]},{"term":"Glomerular filtration rate decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":9,"numAffected":5,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":38,"numAffected":16,"numAtRisk":120},{"groupId":"EG001","numEvents":84,"numAffected":24,"numAtRisk":118},{"groupId":"EG002","numEvents":32,"numAffected":16,"numAtRisk":117}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":283,"numAffected":78,"numAtRisk":120},{"groupId":"EG001","numEvents":327,"numAffected":73,"numAtRisk":118},{"groupId":"EG002","numEvents":220,"numAffected":68,"numAtRisk":117}]},{"term":"Neutrophil count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":120},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":118},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":117}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":109,"numAffected":45,"numAtRisk":120},{"groupId":"EG001","numEvents":137,"numAffected":54,"numAtRisk":118},{"groupId":"EG002","numEvents":64,"numAffected":29,"numAtRisk":117}]},{"term":"Protein total decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":13,"numAffected":2,"numAtRisk":118},{"groupId":"EG002","numEvents":7,"numAffected":5,"numAtRisk":117}]},{"term":"Thyroxine free decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":120},{"groupId":"EG001","numEvents":9,"numAffected":6,"numAtRisk":118},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Thyroxine free increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":12,"numAffected":6,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Total bile acids increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":120},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Tri-iodothyronine free decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":120},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Tri-iodothyronine free increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Urinary occult blood positive","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":15,"numAtRisk":120},{"groupId":"EG001","numEvents":22,"numAffected":17,"numAtRisk":118},{"groupId":"EG002","numEvents":8,"numAffected":8,"numAtRisk":117}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":13,"numAtRisk":120},{"groupId":"EG001","numEvents":15,"numAffected":9,"numAtRisk":118},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":117}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":241,"numAffected":68,"numAtRisk":120},{"groupId":"EG001","numEvents":291,"numAffected":68,"numAtRisk":118},{"groupId":"EG002","numEvents":190,"numAffected":61,"numAtRisk":117}]},{"term":"White blood cell count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":120},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":118},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":117}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":87,"numAffected":55,"numAtRisk":120},{"groupId":"EG001","numEvents":89,"numAffected":55,"numAtRisk":118},{"groupId":"EG002","numEvents":72,"numAffected":37,"numAtRisk":117}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":7,"numAtRisk":120},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":118},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":117}]},{"term":"Hypercholesterolaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":8,"numAtRisk":120},{"groupId":"EG001","numEvents":12,"numAffected":7,"numAtRisk":118},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":117}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":65,"numAffected":22,"numAtRisk":120},{"groupId":"EG001","numEvents":34,"numAffected":15,"numAtRisk":118},{"groupId":"EG002","numEvents":14,"numAffected":10,"numAtRisk":117}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":120},{"groupId":"EG001","numEvents":7,"numAffected":3,"numAtRisk":118},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":117}]},{"term":"Hypermagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":120},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Hypertriglyceridaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":30,"numAffected":16,"numAtRisk":120},{"groupId":"EG001","numEvents":27,"numAffected":8,"numAtRisk":118},{"groupId":"EG002","numEvents":12,"numAffected":8,"numAtRisk":117}]},{"term":"Hyperuricaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":50,"numAffected":18,"numAtRisk":120},{"groupId":"EG001","numEvents":71,"numAffected":15,"numAtRisk":118},{"groupId":"EG002","numEvents":10,"numAffected":6,"numAtRisk":117}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":56,"numAffected":32,"numAtRisk":120},{"groupId":"EG001","numEvents":40,"numAffected":27,"numAtRisk":118},{"groupId":"EG002","numEvents":26,"numAffected":19,"numAtRisk":117}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":15,"numAtRisk":120},{"groupId":"EG001","numEvents":31,"numAffected":10,"numAtRisk":118},{"groupId":"EG002","numEvents":7,"numAffected":5,"numAtRisk":117}]},{"term":"Hypochloraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":11,"numAtRisk":120},{"groupId":"EG001","numEvents":17,"numAffected":11,"numAtRisk":118},{"groupId":"EG002","numEvents":13,"numAffected":11,"numAtRisk":117}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":42,"numAffected":27,"numAtRisk":120},{"groupId":"EG001","numEvents":40,"numAffected":22,"numAtRisk":118},{"groupId":"EG002","numEvents":22,"numAffected":16,"numAtRisk":117}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":8,"numAtRisk":120},{"groupId":"EG001","numEvents":16,"numAffected":9,"numAtRisk":118},{"groupId":"EG002","numEvents":11,"numAffected":7,"numAtRisk":117}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":47,"numAffected":28,"numAtRisk":120},{"groupId":"EG001","numEvents":59,"numAffected":28,"numAtRisk":118},{"groupId":"EG002","numEvents":29,"numAffected":20,"numAtRisk":117}]},{"term":"Hypophosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":6,"numAtRisk":120},{"groupId":"EG001","numEvents":20,"numAffected":7,"numAtRisk":118},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":117}]},{"term":"Hypoproteinaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":17,"numAtRisk":120},{"groupId":"EG001","numEvents":23,"numAffected":11,"numAtRisk":118},{"groupId":"EG002","numEvents":25,"numAffected":12,"numAtRisk":117}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":61,"numAffected":33,"numAtRisk":120},{"groupId":"EG001","numEvents":38,"numAffected":29,"numAtRisk":118},{"groupId":"EG002","numEvents":40,"numAffected":20,"numAtRisk":117}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":14,"numAtRisk":120},{"groupId":"EG001","numEvents":22,"numAffected":20,"numAtRisk":118},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":117}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":120},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":118},{"groupId":"EG002","numEvents":10,"numAffected":6,"numAtRisk":117}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":4,"numAtRisk":120},{"groupId":"EG001","numEvents":8,"numAffected":6,"numAtRisk":118},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":117}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":120},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":118},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":117}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":120},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":118},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":117}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":59,"numAffected":42,"numAtRisk":120},{"groupId":"EG001","numEvents":35,"numAffected":20,"numAtRisk":118},{"groupId":"EG002","numEvents":38,"numAffected":27,"numAtRisk":117}]},{"term":"Cancer pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":120},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":118},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":117}]},{"term":"Tumour pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":120},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":118},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":117}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":120},{"groupId":"EG001","numEvents":11,"numAffected":10,"numAtRisk":118},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":117}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":120},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":35,"numAffected":27,"numAtRisk":120},{"groupId":"EG001","numEvents":13,"numAffected":13,"numAtRisk":118},{"groupId":"EG002","numEvents":30,"numAffected":20,"numAtRisk":117}]},{"term":"Neurotoxicity","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":15,"numAtRisk":120},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":118},{"groupId":"EG002","numEvents":14,"numAffected":12,"numAtRisk":117}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":8,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":117}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":9,"numAtRisk":120},{"groupId":"EG001","numEvents":13,"numAffected":11,"numAtRisk":118},{"groupId":"EG002","numEvents":16,"numAffected":14,"numAtRisk":117}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":22,"numAtRisk":120},{"groupId":"EG001","numEvents":22,"numAffected":19,"numAtRisk":118},{"groupId":"EG002","numEvents":9,"numAffected":8,"numAtRisk":117}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":19,"numAtRisk":120},{"groupId":"EG001","numEvents":17,"numAffected":15,"numAtRisk":118},{"groupId":"EG002","numEvents":12,"numAffected":11,"numAtRisk":117}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":120},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":20,"numAtRisk":120},{"groupId":"EG001","numEvents":23,"numAffected":17,"numAtRisk":118},{"groupId":"EG002","numEvents":18,"numAffected":13,"numAtRisk":117}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":120},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":118},{"groupId":"EG002","numEvents":10,"numAffected":10,"numAtRisk":117}]},{"term":"Tachypnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":120},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":118},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":80,"numAffected":78,"numAtRisk":120},{"groupId":"EG001","numEvents":84,"numAffected":82,"numAtRisk":118},{"groupId":"EG002","numEvents":73,"numAffected":72,"numAtRisk":117}]},{"term":"Dermatitis allergic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":120},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":118},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":117}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":9,"numAtRisk":120},{"groupId":"EG001","numEvents":10,"numAffected":9,"numAtRisk":118},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":117}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":36,"numAffected":25,"numAtRisk":120},{"groupId":"EG001","numEvents":31,"numAffected":28,"numAtRisk":118},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":117}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":120},{"groupId":"EG001","numEvents":10,"numAffected":6,"numAtRisk":118},{"groupId":"EG002","numEvents":6,"numAffected":3,"numAtRisk":117}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \\& may request a further delay to protect its IP rights."},"pointOfContact":{"title":"Study Director","organization":"BeiGene","email":"clinicaltrials@beigene.com","phone":"1-877-828-5568"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2019-08-16","uploadDate":"2023-09-05T18:29","filename":"Prot_000.pdf","size":1074077},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2020-01-02","uploadDate":"2023-09-05T18:30","filename":"SAP_001.pdf","size":442312}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2023-10-12","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000707970","term":"tislelizumab"},{"id":"D017239","term":"Paclitaxel"},{"id":"C520255","term":"130-nm albumin-bound paclitaxel"},{"id":"D016190","term":"Carboplatin"}],"ancestors":[{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D056831","term":"Coordination Complexes"}]}},"hasResults":true}